Key Insights

Highlights

Success Rate

86% trial completion

Published Results

15 trials with published results (15%)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 49/100

Termination Rate

6.2%

6 terminated out of 97 trials

Success Rate

85.7%

-0.8% vs benchmark

Late-Stage Pipeline

5%

5 trials in Phase 3/4

Results Transparency

42%

15 of 36 completed with results

Key Signals

15 with results86% success

Data Visualizations

Phase Distribution

77Total
Not Applicable (19)
Early P 1 (3)
P 1 (23)
P 2 (27)
P 3 (4)
P 4 (1)

Trial Status

Completed36
Recruiting19
Active Not Recruiting16
Unknown9
Terminated6
Not Yet Recruiting5

Trial Success Rate

85.7%

Benchmark: 86.5%

Based on 36 completed trials

Clinical Trials (97)

Showing 20 of 20 trials
NCT04567771Not ApplicableActive Not Recruiting

Comparison of Proton or Intensity Modulated Radiation Therapy After Surgery for Endometrial or Cervical Cancer

NCT04251416Phase 2Active Not RecruitingPrimary

A Study of Sacituzumab Govitecan (IMMU-132) in Endometrial Carcinoma

NCT06365905RecruitingPrimary

Non-Invasive Identification of Endometrial Cancer/Endometrial Atypical Hyperplasia With an AI-Based Classifier Applied to Transvaginal Ultrasound in Patients With Post-Menopausal Bleeding

NCT05316467Phase 2TerminatedPrimary

Weight Management Plus Megestrol Acetate in Early-stage Endometrioid Carcinoma

NCT05256225Phase 3RecruitingPrimary

Testing the Addition of Herceptin Hylecta or Phesgo to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carcinoma or Carcinosarcoma

NCT03671811Phase 2Active Not Recruiting

Megestrol Acetate With or Without Pterostilbene in Treating Patients With Endometrial Cancer Undergoing Hysterectomy

NCT02465060Phase 2Active Not Recruiting

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

NCT05919264Phase 1Recruiting

FOG-001 in Locally Advanced or Metastatic Solid Tumors

NCT06102252Not ApplicableCompletedPrimary

Combination Chemotherapy of Paclitaxel and Carboplatin With or Without Anthracycline as Aneo Adjuvant Treatment in Advanced Endometrial Carcinoma

NCT04634617Active Not RecruitingPrimary

Pelvic Floor Dysfunction and Quality of Life in Uterine Cancer Survivors

NCT07285044Phase 2Recruiting

The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and Improve Treatment Satisfaction in Cancer Patients Living in the Florida Panhandle and Surrounding Areas

NCT07279571Not Yet RecruitingPrimary

GYN-AIDE: Gynecologic Oncology Navigation Through AI-Driven Education

NCT04152499Phase 1Active Not Recruiting

Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies (KL264-01)

NCT06790004Active Not RecruitingPrimary

Endometrial Carcinoma: Comparison of Surgical Approaches (Laparoscopy vs Laparotomy)

NCT04713618Active Not Recruiting

Changes in Pelvic Health, Sexual Function, and Quality of Life in Women With Pelvic Cancer Undergoing Radiation Therapy

NCT04851119Phase 1Recruiting

Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors

NCT07146919Phase 1WithdrawnPrimary

AssociatiNG Bevacizumab bEmarituzumab for GynecoLogIcal CAncer

NCT04678414Active Not Recruiting

Infertility Survey Among Reproductive Age Women With Gynecological and Breast Cancer

NCT07527143Not Yet RecruitingPrimary

Acceptability of Testing DNA Markers in Vaginal Fluid for the Detection of Endometrial Cancer

NCT01366144Phase 1Active Not Recruiting

Veliparib, Paclitaxel, and Carboplatin in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery and Liver or Kidney Dysfunction

Scroll to load more

Research Network

Activity Timeline